Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
6
×
life sciences
clinical trials
national blog main
new york top stories
indiana blog main
indiana top stories
national
national top stories
new york blog main
san francisco top stories
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
europe top stories
fda
novartis
raleigh-durham blog main
raleigh-durham top stories
roche
san diego blog main
san diego top stories
san francisco blog main
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
amgen
biogen
cancer
diagnostics
drug prices
europe blog main
gene therapy
immunotherapy
What
drug
6
×
patients
6
×
fda
medicine
bio
market
new
roundup
today
type
acquisitions
advantages
albert
approval
approved
atrophy
bar
bid
biggest
biologic
boehringer
bottleneck
bourla
brings
cancer
ceo
clinical
company
crispr
daily
development
diabetes
dramatically
eisai
eli
evrysdi
expand
expect
fallen
fixing
Language
unset
unknown
Current search:
drug
×
biotech
×
patients
×
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
6 years ago
Fixing the Clinical Trial Bottleneck by Making Patients a Priority